"Prototype Drug Uses Novel Mechanism To Treat Lung Cancers"
Cells are constantly turning proteins on and off via molecular switches-phosphate molecules-that have become common drug targets. Researchers collaborated to screen a series of drug-like molecules for their ability to reactivate PP2A in lung cancer cells and prevent lung cancer tumors in mice. The prototype drug molecules were created from FDA-approved medications by Michael Ohlmeyer, PhD, an associate professor of pharmacological sciences at the Icahn School of Medicine at Mount Sinai.
- Michael Ohlmeyer, PhD, Associate Professor of Pharmacological Sciences at the Icahn School of Medicine at Mount Sinai
Learn more
Mount Sinai Scientists Create AI-Powered Tool to Improve Cancer Tissue Analysis
Aug 25, 2025 View All Press Releases
Combination Therapy Improves Outcomes for Advanced Triple-Negative Breast Cancer
Aug 21, 2025 View All Press Releases
The Mount Sinai Hospital Ranked Among Top in the Nation by U.S. News & World Report®
Jul 29, 2025 View All Press Releases
Mount Sinai Researchers Engineer Rare Immune Cells to Create Powerful New Cancer Vaccine
Jul 21, 2025 View All Press Releases
Mount Sinai’s Cancer Science in the Spotlight at 2025 ASCO
May 29, 2025 View All Press Releases